Teladoc Health (NYSE:TDOC – Get Free Report) had its price objective decreased by equities researchers at Citigroup from $29.00 to $21.00 in a research report issued on Friday, Benzinga reports. The firm presently has a “neutral” rating on the health services provider’s stock. Citigroup’s target price indicates a potential upside of 13.76% from the stock’s previous close.
A number of other brokerages also recently issued reports on TDOC. StockNews.com assumed coverage on Teladoc Health in a research report on Thursday, October 5th. They set a “sell” rating on the stock. Evercore ISI reduced their price target on Teladoc Health from $25.00 to $19.00 in a research report on Wednesday, October 11th. Finally, Truist Financial reaffirmed a “hold” rating and set a $28.00 price target on shares of Teladoc Health in a research report on Monday, September 25th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $29.88.
View Our Latest Research Report on Teladoc Health
Teladoc Health Stock Up 1.7 %
Teladoc Health stock opened at $18.46 on Friday. The business has a fifty day moving average of $20.81 and a two-hundred day moving average of $23.66. The company has a quick ratio of 3.36, a current ratio of 3.45 and a debt-to-equity ratio of 0.67. The firm has a market cap of $3.04 billion, a P/E ratio of -0.75 and a beta of 1.14. Teladoc Health has a twelve month low of $17.78 and a twelve month high of $34.73.
Teladoc Health (NYSE:TDOC – Get Free Report) last posted its earnings results on Tuesday, July 25th. The health services provider reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.04. The company had revenue of $652.41 million during the quarter, compared to analyst estimates of $649.20 million. Teladoc Health had a negative return on equity of 7.32% and a negative net margin of 158.76%. Teladoc Health’s revenue was up 10.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.44) earnings per share. On average, analysts forecast that Teladoc Health will post -1.36 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Teladoc Health news, insider Claus Torp Jensen sold 6,547 shares of the stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $29.00, for a total transaction of $189,863.00. Following the sale, the insider now directly owns 13,096 shares of the company’s stock, valued at approximately $379,784. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Teladoc Health news, insider Claus Torp Jensen sold 6,547 shares of the stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $29.00, for a total transaction of $189,863.00. Following the sale, the insider now directly owns 13,096 shares of the company’s stock, valued at approximately $379,784. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jason N. Gorevic sold 10,000 shares of the stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $30.03, for a total value of $300,300.00. Following the sale, the chief executive officer now directly owns 596,246 shares in the company, valued at $17,905,267.38. The disclosure for this sale can be found here. In the last three months, insiders have sold 25,835 shares of company stock valued at $695,528. Company insiders own 1.63% of the company’s stock.
Institutional Investors Weigh In On Teladoc Health
Hedge funds have recently modified their holdings of the company. Level Four Advisory Services LLC boosted its stake in shares of Teladoc Health by 1.3% during the 2nd quarter. Level Four Advisory Services LLC now owns 41,157 shares of the health services provider’s stock worth $1,042,000 after acquiring an additional 547 shares in the last quarter. Chiron Capital Management LLC lifted its stake in Teladoc Health by 13.3% in the 1st quarter. Chiron Capital Management LLC now owns 19,393 shares of the health services provider’s stock valued at $502,000 after buying an additional 2,276 shares in the last quarter. Prosight Management LP purchased a new position in Teladoc Health in the 1st quarter valued at about $1,189,000. LPL Financial LLC lifted its stake in Teladoc Health by 18.5% in the 1st quarter. LPL Financial LLC now owns 123,207 shares of the health services provider’s stock valued at $3,191,000 after buying an additional 19,249 shares in the last quarter. Finally, Titleist Asset Management LLC purchased a new position in Teladoc Health in the 1st quarter valued at about $1,092,000. 77.07% of the stock is owned by hedge funds and other institutional investors.
Teladoc Health Company Profile
Teladoc Health, Inc provides virtual healthcare services in the United States and internationally. The company operates through two segments, Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
Further Reading
Receive News & Ratings for Teladoc Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Teladoc Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
